Cyclooxygenase 2 mediates the antiangiogenic effect of rapamycin in Ewing sarcoma

Journal of Pediatric Surgery

Volumn 44, Issue 6, 2009, Pages 1139-1147

  Lipskar, Aaron M ^a,d   Glick, Richard D ^a   Huang, Jianzhong ^c   Fisher, Jason C ^c   DeVoti, James ^d   Pica, Ray ^d   Edelman, Morris ^a   Steinberg, Bettie M ^b,d   Soffer, Samuel Z ^a,d  

^a SCHNEIDER CHILDREN'S HOSPITAL   (United States)

^b North Shore LIJ Health System ^*  (United States)

^c Columbia University ^*  (United States)

^d FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Anti angiogenesis; Cyclooxygenase 2; Ewing sarcoma; Rapamycin

Indexed keywords

CYCLOOXYGENASE 2; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PROTEIN; PROTEIN KINASE B; RAPAMYCIN; S6 KINASE;

ANGIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; EWING SARCOMA; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT DURATION; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; SARCOMA, EWING'S; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 66649122272     PISSN: 00223468     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpedsurg.2009.02.037     Document Type: Article

References (32)

1. Detattre O., Zucman J., Melot T., et al. The Ewing family of tumors-a subgroup of small-round-cell tumors defined by specific chimeric transcripts. NEJM 331 (1994) 294-299
2. Lewis I., Burchill S., and Souhami R. Ewing's sarcoma and the Ewing family of tumours. In: Souhami R.L., Tannock I., Hohenberger P., and Horiot J.C. (Eds). Oxford textbook of oncology (2002), Oxford University Press, Oxford 2538-2551
3. Folkman J. Tumor angiogenesis. In: Mendelsohn J., Howley P.A.M., Israel M.A., and Liotta L.A. (Eds). The molecular basis of cancer (1995), W.B. Saunders Co., Philadelphia 206-232
4. Kim K.J., Li B., Winer J., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362 (1993) 841-844
5. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. NEJM 349 (2003) 427-434
6. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, flouracil, and leucovorin for metastatic colorectal cancer. NEJM 350 (2004) 2335-2342
7. Rowe D.H., Huang J., Kayton M.L., et al. Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor. J Pediatr Surg 35 (2000) 30-33
8. Boehm T., Folkman J., Browder T., et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390 (1997) 404-407
9. Huang J., Soffer S.Z., Kim E., et al. Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol Cancer Res 2 (2004) 36-42
10. Hay N., and Sonenberg N. Upstream and downstream of mTOR. Genes Dev 18 (2004) 1926-1945
11. Abraham R.T., and Gibbons J.J. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 13 (2007) 3109-3114
12. Luan F.L., Hojo M., Maluccio M., et al. Rapamycin blocks tumor progression unlinking immunosuppression from antitumor efficacy. Transplantation 73 (2002) 1565-1572
13. Browder T., Butterfield C.E., Kräling B.M., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 61 (2000) 1878-1886
14. Hanahan D., Bergers G., and Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105 (2000) 1045-1047
15. Guba M., Von Breitenbuch P., Steinbauer M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Na Med 8 (2002) 128-135
16. Phung T.L., Ziv K., Dabydeen D., et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 10 (2006) 159-170
17. Luan F.L., Ding R., Sharma V.K., et al. Ramaycin is an effective inhibitor of human renal cancer metastasis. Kidney Intl 63 (2003) 917-926
18. Jung Y.J., Isaacs J.S., Lee S., et al. L. IL-1β-mediated up-regulation of HIF-1α via an NFκB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J (2003)
19. Mizukami Y., Kohgo Y., and Chung D.C. Hypoxia inducible factor-1-independent pathways in tumor angiogenesis. Clin Cancer Res 13 (2007) 5670-5674
20. Hocherl K., Hensel C., Ulbricht B., et al. Everolimus treatment downregulates renocortical cyclooxygenase-2 expression in the rat kidney. Br J Pharmacol 145 (2005) 1112-1122
21. Smith M.A., Morton C.L., Phelps D., et al. SK-NEP-1 and Rh1 are Ewing family tumor lines. Pediatr Blood Cancer 50 3 (2006) 703-706
22. Wu R., Abramson A.L., Shikowitz M.J., et al. Epidermal growth factor-induced cyclooxygenase-2 expression is mediated through phosphatidylinositol-3 kinase, not mitogen-activated protein/extracellular signal-regulated kinase kinase, in recurrent respiratory papillomas. Clin Cancer Res 11 17 (2005) 6155-6161
23. Auborn K.J., Fan S., Rosen E.M., et al. Indole-3-carbinol is a negative regulator of estrogen. J Nutr 133 (2003) 2470-2475
24. Brown L.F., Detmar M., Claffey K., et al. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. In: Goldberg I.D., and Rosen E. (Eds). Control of Angiogenesis (1996), Birkhauser Verlag, Berlin 1-9
25. Casanovas O., Hicklin D.J., Bergers G., et al. Drug resistance by evasion of antiangiogenic targeting if VEGF signaling in late-stage pancreatic islet cell tumors. Cancer Cell 8 (2005) 299-309
26. Sarbassov D.D., Ali S.M., and Sabatini D.M. Growing roles for the MTOR pathway. Curr Opin Cell Biol 17 (2005) 596-603
27. Guba M., Koehl G.E., Neppl E., et al. Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. Transpl Int 18 (2005) 89-94
28. Phung T.L., Eyiah-Mensah G., O'Doneell R.K., et al. Endothelial Akt signaling is rate-limiting for rapamycin inhibition of mouse mammary tumor progression. Cancer Res 67 (2007) 5070-5075
29. Del Bufalo D., Ciuffreda L., Trisciuogli D., et al. Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 66 (2006) 5549-5554
30. Masferrer J.L., Leahy K.M., Koki A.T., et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60 (2000) 106-1311
31. Form D.M., and Auerbach R. PGE2 and angiogenesis. Proc Soc Exp Biol Med 172 (1983) 214-218
32. Lee A., Frischer J., Serur A., et al. Inhibition of cyclooxygenase-2 disrupts tumor vascular mural cell recruitment and survival signaling. Cancer Res 66 (2006) 4378-4384